CYTOKINETICS, INCORPORATED Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
CYTOKINETICS, INCORPORATED (CYTK) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $21.22 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2017-03-31 was $6.83.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2015-03-31 was $6.24, a 4.00% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2014-03-31 was $6.00.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $21.22, a 5.05% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $20.20, a 66.53% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $12.13, a 19.74% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $10.13, a 12.43% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $21.22 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $20.20 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | $12.13 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $10.13 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $9.01 10-K · filed 2024-02-28 | ||||
| 2020-12-31 | $8.27 10-K · filed 2023-03-01 | ||||
| 2019-12-31 | $7.78 10-K · filed 2021-02-26 | ||||
| 2018-12-31 | $7.51 10-K · filed 2019-03-07 | ||||
| 2017-12-31 | $7.26 10-K · filed 2018-03-05 | ||||
| 2017-09-30 | $7.33 10-Q · filed 2017-11-03 | ||||
| 2017-06-30 | $7.09 10-Q · filed 2017-08-04 | ||||
| 2017-03-31 | $6.83 10-Q · filed 2017-05-04 | ||||
| 2016-12-31 | $6.75 10-K · filed 2017-03-06 | ||||
| 2016-09-30 | $6.44 10-Q/A · filed 2016-12-15 | ||||
| 2016-06-30 | $5.83 10-Q · filed 2016-08-04 | ||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-05 | ||||
| 2015-12-31 | $6.22 10-K · filed 2017-03-06 | ||||
| 2015-09-30 | $6.12 10-Q · filed 2015-11-05 | ||||
| 2015-06-30 | $6.23 10-Q · filed 2015-08-05 | ||||
| 2015-03-31 | $6.24 10-Q · filed 2015-05-04 | ||||
| 2014-12-31 | $6.00 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | $6.00 10-Q · filed 2014-11-06 | ||||
| 2014-06-30 | $6.00 10-Q · filed 2014-08-07 | ||||
| 2014-03-31 | $6.00 10-Q · filed 2014-05-07 | ||||
| 2013-12-31 | $5.32 10-K · filed 2016-03-03 | ||||
| 2013-09-30 | $5.32 10-Q · filed 2013-11-06 | ||||
| 2013-06-30 | $9.24 10-Q · filed 2013-08-07 | ||||
| 2011-12-31 | $6.56 10-K · filed 2014-03-07 | $1.09 10-K · filed 2013-03-15 | |||
| 2010-12-31 | $1.12 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |